Ben-Baruch A, Xu L, Young P R, Bengali K, Oppenheim J J, Wang J M
Laboratory of Molecular Immunoregulation, SAIC Frederick, National Cancer Institute, Frederick Cancer Research and Development Center, Maryland 21702, USA.
J Biol Chem. 1995 Sep 22;270(38):22123-8. doi: 10.1074/jbc.270.38.22123.
Monocyte chemotactic protein-3 (MCP3) is recently identified and molecularly cloned C-C chemokine that is chemotactic for and activates a great variety of inflammatory cell types. MCP3 has been reported to interact with several C-C chemokine receptors, which can be simultaneously or selectively expressed on leukocyte subpopulations. In order to isolate receptor(s) for MCP3, a cDNA library was constructed using mRNA from a human NK-like cell line, YT. These cells showed high affinity binding sites for 125I-MCP3 and migrated in response to MCP3. A chemokine receptor cDNA clone, designated YT4, was sequenced and found to be identical to the known C-C CKR1 or macrophage inflammatory protein-1 alpha (MIP1 alpha)/Rantes receptor. YT4 cDNA was subcloned into a mammalian expression vector, and stable transfectants were prepared using the embryonic kidney cell line 293. The transfectants (YT4/293) showed high affinity binding for 125I-MCP3 in addition to specifically binding 125I-MIP1 alpha and 125I-Rantes. All three C-C chemokines were able to cross-compete for binding sites on YT4/293 cells and induced directional migration of YT4/293 cells in vitro, with MCP3 being the most potent chemoattractant. MCP3, MIP1 alpha, and Rantes were equally able to cross-attenuate the migratory response of YT4/293 cells to one another. In contrast, MCP1 and MIP1 beta had very limited capacity to compete for MCP3 binding on YT4/293 cells and had only a minor attenuating effect on MCP3-induced migration. Since MCP3 has been reported to use MCP1 receptor(s), our results with transfected 293 cells expressing only C-C CKR1 clearly establish that C-C CKR1 is also a functional receptor for MCP3.
单核细胞趋化蛋白-3(MCP3)是最近被鉴定和分子克隆的C-C趋化因子,它对多种炎症细胞类型具有趋化作用并能激活这些细胞。据报道,MCP3可与多种C-C趋化因子受体相互作用,这些受体可同时或选择性地在白细胞亚群上表达。为了分离MCP3的受体,利用来自人NK样细胞系YT的mRNA构建了一个cDNA文库。这些细胞对125I-MCP3显示出高亲和力结合位点,并对MCP3产生迁移反应。对一个名为YT4的趋化因子受体cDNA克隆进行测序,发现它与已知的C-C CKR1或巨噬细胞炎性蛋白-1α(MIP1α)/RANTES受体相同。将YT4 cDNA亚克隆到哺乳动物表达载体中,并使用胚胎肾细胞系293制备稳定转染子。转染子(YT4/293)除了能特异性结合125I-MIP1α和125I-RANTES外,对125I-MCP3也显示出高亲和力结合。所有这三种C-C趋化因子都能够在YT4/293细胞上竞争结合位点,并在体外诱导YT4/293细胞的定向迁移,其中MCP3是最有效的趋化剂。MCP3、MIP1α和RANTES同样能够相互交叉减弱YT4/293细胞的迁移反应。相比之下,MCP1和MIP1β竞争YT4/293细胞上MCP3结合的能力非常有限,并且对MCP3诱导的迁移只有轻微的减弱作用。由于据报道MCP3使用MCP1受体,我们对仅表达C-C CKR1的转染293细胞的研究结果清楚地表明,C-C CKR1也是MCP3的功能性受体。